Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute’s Innovative Drug Development Initiative – Group 3 Pulmonary Hypertension

By sjmartinez • April 8, 2023

Piccari L, Allwood B, Antoniou K, Chung JH, Hassoun PM, Nikkho SM, Saggar R, Shlobin OA, Vitulo P, Nathan SD, Wort SJ. Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative - Group 3 Pulmonary Hypertension. Pulm Circ. 2023 Apr 1;13(2):e12213. doi: 10.1002/pul2.12213. PMID: 37025209; PMCID: PMC10071306.

Tags: endophenotype, histology, idiopathic pulmonary fibrosis, pathophysiology, Publications, pulmonary vascular disease, Pulmonary, Critical Care & Sleep Medicine

Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer

Silverstein J, Smick A, Johnson B, Konecny GE. Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer. Future Oncol. 2025[...]

Supplemental Oxygen during Exercise Training in Chronic Obstructive Pulmonary Disease

Faggian S, Battista F, Vecchiato M, Casaburi R, Emtner M, Borasio N, Studnicka M, Ermolao A, Niebauer J, Neunhaeuserer D. Supplemental Oxygen during Exercise Training[...]

DNA methylation patterns in breast cancer, paired benign tissue from ipsilateral and contralateral breast, and healthy controls

Dennis SR, Tsukioki T, Cottone G, Zhou W, Ganz PA, Sehl ME, Luo Y, Khan SA, Clare S. DNA methylation patterns in breast cancer, paired[...]